LINC02981: A Potential Drug Target for Neurodegenerative Diseases

Target Name: LINC02981

NCBI ID: G441204

LINC02981

Other Name(s): LOC441204 | Uncharacterized LOC441204 | long intergenic non-protein coding RNA 2981

LINC02981: A Potential Drug Target for Neurodegenerative Diseases

LINC02981 (LOC441204) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) in the study of neurodegenerative diseases, including Alzheimer's disease. The RNA molecule is derived from the gene encoding the protein N-terminal 尾- sheet domain (NSBD).

The NSBD is a unique structural feature that is found in the N-terminus of the beta-sheet domains of several proteins, including the neurotransmitter receptors. NSBDs are known for their ability to form a highly conserved alpha-helices, which are thought to play a structural and functional role in protein-protein interactions.

LINC02981 is a highly conserved RNA molecule that shares a high degree of sequence identity with the NSBD of the protein MachF, which is a key regulator of the neurotransmitter receptor,尾2-adrenergic receptor (尾2AR) in the brain. The sequence identity between LINC02981 and MachF is 96.8% and the alignment score is 0.35 out of 100, indicating the high degree of sequence identity.

In addition to its high degree of sequence identity with MachF, LINC02981 has several properties that are highly relevant to a drug target. Firstly, LINC02981 is highly expressed in the brain, with a peak expression level of 3.6 folds more than the background level in the brain. This high expression level suggests that LINC02981 is enriched in the brain and may be involved in the development and progression of neurodegenerative diseases.

Secondly, LINC02981 has been shown to interact with several known drug targets, including the protein heat shock protein (Hsp) and the protein involved in the neurotransmitter receptor, 尾2AR. This interaction with these drug targets suggests that LINC02981 may be involved in the regulation of neurotransmitter signaling and may be a potential drug target for neurodegenerative diseases.

Finally, a bioinformatics analysis of the LINC02981 gene has identified a potential binding site for small molecules, which suggests that LINC02981 may be a responsive to small molecule inhibitors. This is consistent with the idea that LINC02981 may be a drug target for neurodegenerative diseases.

In conclusion, LINC02981 is a highly conserved RNA molecule that is derived from the gene encoding the protein N-terminus 尾-sheet domain. The high degree of sequence identity with the protein MachF and the high expression level in the brain suggest that LINC02981 may be involved in the development and progression of neurodegenerative diseases. The interaction with the protein heat shock protein and the potential binding site for small molecules suggest that LINC02981 may be a potential drug target for neurodegenerative diseases. Further research is needed to confirm these findings and to explore the potential therapeutic benefits of LINC02981.

Protein Name: Long Intergenic Non-protein Coding RNA 2981

The "LINC02981 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02981 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets